U.S. FDA refuses to review Zogenix's seizure treatment

The U.S. Food and Drug Administration on Monday refused to review the marketing application for Zogenix Inc's treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy, the company said.